Sangamo Biosciences reported $-42429000 in EBITDA for its first fiscal quarter of 2022.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Ebitda Change
Alnylam Pharmaceuticals ALNY:US $ -137.27M 45.91M
Amgen AMGN:US $ 3341M 185M
Avrobio Inc AVRO:US $ -29019000 1.49M
Biocryst Pharmaceuticals BCRX:US $ -49.64M 2.37M
Biogen BIIB:US $ 674.7M 20.2M
Biomarin Pharmaceutical BMRN:US $ 56.67M 96.56M
Gilead Sciences GILD:US $ 3422M 1947M
GlaxoSmithKline GSK:LN 3120M 1062M
Intercept Pharmaceuticals ICPT:US $ -9.9M 10.55M
IONIS PHARMACEUT IONS:US $ -53.21M 278.25M
Johnson & Johnson JNJ:US $ 9309M 1549M
Karyopharm Therapeutics KPTI:US $ -34409000 81.51M
Merk MRK:US $ 6179M 492M
Novartis NOVN:VX SF 4552M 346M
Pfizer PFE:US $ 11182M 4046M
Regulus Therapeutics RGLS:US $ -6.54M 0.28M
Sangamo Biosciences SGMO:US $ -42.43M 5.29M
Sarepta Therapeutics SRPT:US $ -76.16M 19.51M
Ultragenyx Pharmaceutical RARE:US $ -132.54M 33.51M
Vertex Pharmaceuticals VRTX:US $ 1069.3M 159.74M
Ziopharm Oncology ZIOP:US $ -8.4M 1.21M